Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
State-of-the-Art Drug Discovery and Development in Poland (2nd Edition)
share announcement

State-of-the-Art Drug Discovery and Development in Poland (2nd Edition)

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".

Deadline for manuscript submissions: 15 March 2025 | Viewed by 2221

Special Issue Editor

Dr. Aleksandra Romaniuk-Drapała

E-Mail Website
Guest Editor
Department of Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, Collegium Pharmaceuticum, 3 Rokietnicka Str., 60-806 Poznan, Poland
Interests: combination chemotherapy; drug delivery; targeted therapy; cancer biology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Over the last few decades, we have observed a significant shift in drug design and development methods. Two distinct technological trends are involved in this change. One represents advances made in exploring areas such as genomic sequencing, protein science, and structural biology. New technologies provide vast numbers of data, uncover a wide range of potential drug targets, and facilitate more accurate target identification and validation. The second trend involves the empowerment of computational scientists to utilize these massive databases thanks to the significant number of tools and software packages available for analyzing and interpreting biological complexity. Technological advances in various areas of omics have allowed the exploration of different approaches to improve the success of drug design and development.

All authors who are actively involved in drug discovery and development in Poland are invited to contribute to this Special Issue. Original research articles and reviews on the hottest topics related to identifying and introducing new medicines and cutting-edge methodological advances are welcome.

Possible research topics include, but are not limited to, the following:

  • In silico drug target profiling;
  • Drug delivery systems;
  • Drug–drug interactions;
  • Target-based screening;
  • Phenotypic screening;
  • Pharmaceutical modeling;
  • Computational chemistry;
  • Targeted therapy;
  • Biomarkers;
  • Bioimaging.

Dr. Aleksandra Romaniuk-Drapała
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • in silico drug target profiling
  • drug delivery systems
  • drug–drug interactions
  • target-based screening
  • phenotypic screening
  • pharmaceutical modeling
  • computational chemistry
  • targeted therapy
  • biomarkers
  • bioimaging

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

22 pages, 839 KiB  
Article
Evaluating the Efficacy of Pre-Emptive Peribulbar Blocks with Different Local Anesthetics or Paracetamol Using the Adequacy of Anesthesia Guidance for Vitreoretinal Surgeries: A Preliminary Report
by Michał Jan Stasiowski, Anita Lyssek-Boroń, Katarzyna Krysik, Dominika Majer, Nikola Zmarzły and Beniamin Oskar Grabarek
Biomedicines 2024, 12(10), 2303; https://doi.org/10.3390/biomedicines12102303 - 10 Oct 2024
Viewed by 373
Abstract
Background/Objectives: Precisely selected patients require vitreoretinal surgeries (VRS) performed under general anesthesia (GA) when intravenous rescue opioid analgesics (IROA) are administered intraoperatively, despite a risk of adverse events, to achieve hemodynamic stability and proper antinociception and avoid the possibility of intolerable postoperative pain [...] Read more.
Background/Objectives: Precisely selected patients require vitreoretinal surgeries (VRS) performed under general anesthesia (GA) when intravenous rescue opioid analgesics (IROA) are administered intraoperatively, despite a risk of adverse events, to achieve hemodynamic stability and proper antinociception and avoid the possibility of intolerable postoperative pain perception (IPPP). Adequacy of anesthesia guidance (AoA) optimizes the titration of IROA. Preventive analgesia (PA) techniques and intravenous or preoperative peribulbar block (PBB) using different local anesthetics (LAs) are performed prior to GA to optimize IROA. The aim was to analyze the utility of PBBs compared with intravenous paracetamol added to AoA-guided GA on the incidence of IPPP and hemodynamic stability in patients undergoing VRS. Methods: A total of 185 patients undergoing vitreoretinal surgery (VRS) were randomly assigned to one of several anesthesia protocols: general anesthesia (GA) with analgesia optimized through AoA-guided intraoperative remifentanil opioid analgesia (IROA) combined with a preemptive single dose of 1 g of paracetamol (P group), or PBB using one of the following options: 7 mL of an equal mixture of 2% lidocaine and 0.5% bupivacaine (BL group), 7 mL of 0.5% bupivacaine (BPV group), or 7 mL of 0.75% ropivacaine (RPV group). According to the PA used, the primary outcome measure was postoperative pain perception assessed using the numeric pain rating scale (NPRS), whereas the secondary outcome measures were as follows: demand for IROA and values of hemodynamic parameters reflecting quality or analgesia and hemodynamic stability. Results: A total of 175 patients were finally analyzed. No studied PA technique proved superior in terms of rate of incidence of IPPP, when IROA under AoA was administered (p = 0.22). PBB using ropivacaine resulted in an intraoperative reduction in the number of patients requiring IROA (p = 0.002; p < 0.05) with no influence on the dose of IROA (p = 0.97), compared to paracetamol, and little influence on hemodynamic stability of no clinical relevance in patients undergoing VRS under AoA-guided GA. Conclusions: PA using paracetamol or PBBs, regardless of LAs used, in patients undergoing VRS proved no advantage in terms of rate of incidence of IPPP and hemodynamic stability when AoA guidance for IROA administration during GA was utilized. Therefore, PA using them seems no longer justified due to the potential, although rare, side effects. Full article
(This article belongs to the Special Issue State-of-the-Art Drug Discovery and Development in Poland (2nd Edition))
►▼ Show Figures

Figure 1

Review

Jump to: Research

12 pages, 279 KiB  
Review
The Use of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer Treatment—Literature Review
by Anita Gorzelak-Magiera, Małgorzata Domagała-Haduch, Jacek Kabut and Iwona Gisterek-Grocholska
Biomedicines 2024, 12(10), 2308; https://doi.org/10.3390/biomedicines12102308 - 11 Oct 2024
Viewed by 588
Abstract
Lung cancer is the leading cause of cancer-related morbidity and mortality. The median survival time for patients with advanced non-small-cell lung cancer before the era of molecular-based personalized treatment was 7.9 months. The discovery of predictive factors and the introduction of molecular diagnostics [...] Read more.
Lung cancer is the leading cause of cancer-related morbidity and mortality. The median survival time for patients with advanced non-small-cell lung cancer before the era of molecular-based personalized treatment was 7.9 months. The discovery of predictive factors and the introduction of molecular diagnostics into daily practice made a breakthrough, enabling several years of survival in patients with advanced disease. The discovery of rearrangements in the ALK gene and ALK tyrosine kinase inhibitors has resulted in a dramatic improvement in the prognosis of patients with this subtype of cancer. Currently, three generations of ALK inhibitors differing in activity, toxicity and degree of penetration into the central nervous system are available in clinical practice. The current state of knowledge on ALK inhibitors used in clinical practice is summarised in this research paper. Methods of diagnosis of abnormalities in ALK have been shown, and the review of research that contributed to the development of the next generation of ALK inhibitors has been presented. Full article
(This article belongs to the Special Issue State-of-the-Art Drug Discovery and Development in Poland (2nd Edition))
18 pages, 1339 KiB  
Review
Epinephrine, Pregabalin, and Crizotinib as Three Medicines with Polish Implications over Three Last Centuries and in View of Three Different Drug Discovery Approaches
by Piotr Kawczak, Igor Feszak and Tomasz Bączek
Biomedicines 2024, 12(9), 2021; https://doi.org/10.3390/biomedicines12092021 - 4 Sep 2024
Viewed by 716
Abstract
The discovery of epinephrine (adrenaline) and its subsequent implications in medicine owes significant contributions to Cybulski across different centuries, who, in 1894, was pivotal in identifying the adrenal medulla’s role in blood pressure regulation and naming the active substance “nadnerczyna”, known [...] Read more.
The discovery of epinephrine (adrenaline) and its subsequent implications in medicine owes significant contributions to Cybulski across different centuries, who, in 1894, was pivotal in identifying the adrenal medulla’s role in blood pressure regulation and naming the active substance “nadnerczyna”, known today as adrenaline. His work demonstrated the adrenal glands’ critical function in the body’s regulatory mechanisms beyond the nervous system. Cybulski’s groundbreaking research laid foundational knowledge for future endocrinological studies and pharmaceutical advancements. In the late 20th century, Andruszkiewicz collaborated with Silverman at Northwestern University to develop pregabalin, the active ingredient in Lyrica. Their innovative synthesis of gamma-aminobutyric acid derivatives led to a significant advancement in treating epilepsy, neuropathic pain, and fibromyalgia. Andruszkiewicz’s expertise in organic chemistry and enzymology was crucial in this collaborative effort, resulting in the successful development and commercialization of Lyrica. Additionally, Mroczkowski’s leadership at Pfizer contributed to the development of crizotinib, a notable anaplastic lymphoma kinase and proto-oncogene 1 tyrosine-protein kinase inhibitor used to treat specific types of non-small cell lung cancer. Her work exemplifies the continuing influence of Polish researchers in pioneering drug discovery and advancing therapeutic treatments over the past three centuries. These contributions highlight Poland’s significant role in global pharmaceutical innovations and medical research. Full article
(This article belongs to the Special Issue State-of-the-Art Drug Discovery and Development in Poland (2nd Edition))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop